Company: AstraZeneca
Posted by CVRMRep_AZ_Heartland_3312 · March 17, 2026
Tags: field, strategy, quota
both drugs have outcomes data.
both have HF.
both have CKD.
what actually moves share: formulary, legacy relationships, who shows up more.
thats it DAPA-HF in HFrEF is the only thing that opens doors differently.
leading with that.
13 upvotes · 4 comments